Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > August 1, 2022
Daily News
August 1, 2022
- Japan’s Fertility Treatment Market to Grow 44.4% by 2025: Fuji Keizai
August 1, 2022
- JPWA Chief Questions Patient Benefits of Single-Wholesaler Distribution
August 1, 2022
- Daiichi Sankyo Q1 Sales Rise 6.2% on Robust Enhertu Performance, Weaker Yen
August 1, 2022
- Japan OKs FY2023 Budget Guidelines, 560 Billion Yen Cap for Social Security Cost Rise
August 1, 2022
- Otsuka’s H1 Pharma Sales Rise 12% on Global Brands, Profits Drop 26.2%
August 1, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Clear MHLW Panel, September Approval Likely
August 1, 2022
- Sumitomo’s Q1 Sales Zoom 22% on FX, Cancer Drug License Fee
August 1, 2022
- MHLW Flags Hoarding of Acetaminophen, Ayumi Stops Supply of 2 Dosage Forms
August 1, 2022
- MSD Files 15-Valent Pneumococcal Vaccine for Pediatric Use in Japan
August 1, 2022
- Servier, Yakult to Wind Up Onivyde Promotion Deal in Japan
August 1, 2022
- PMDA Reviewing Safety Risks for Plaquenil, Cyramza
August 1, 2022
- KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…